Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Amgen, Inc. will employ Plexium, Inc.'s targeted protein degradation technology to seek therapies for historically challenging drug targets under a multi-year collaboration and licensing agreement unveiled on 3 February